Clinical Trial Search

Primary: Number of Subjects With an Investigator Assessment of Clinical Outcome (Success/Failure) at End of Study — 275; 133 participants

Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants

Primary: Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4 — 12.96; 12.87; 12.71 units on a scale

Primary: Total Symptoms Score (TSS) — 0.503; 0.843 scores

Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants

Primary: Antibiotic Sparing — 89; 121 Participants — p=0.025

Primary: Health Related Quality of Life Score — 91.5; 90.2 scores on a scale — p=0.008

Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year

Primary: Average Duration of Fever. — 3.1; 3.6 days — p=0.0174

Primary: Body Temperature — 183; 170; 13; 2617 Participants

Primary: Average Illness Duration (the Interval Between the Start of the Trial Treatment and the Time When Recovery/Improvement - Based on Patient Diary Data) — 87.7; 103.3 hours…

Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001

Primary: Number of Participants With a Clinical Outcome of "Cure" at Test of Cure (TOC: Day 15) — 23; 3; 0 Participants

Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml

Primary: Total Symptom Score (TSS) Area Under the Curve (AUC) — 93.64; 62.53; 73.75; 78.34 days x Score

Primary: Percentage of Patients With Recovery/Improvement in Health on Days 2, 3 and 4 of Observation (Based on Patient Diary Data) — 9; 1; 21; 11 percentage of participants…

Primary: Number of Patients With Adverse Events (AEs) — 27 participants

Primary: Progression to Clinically Significant Lower Respiratory Tract Symptoms — 35; 57 participants — p=0.04

Primary: Average Time From Baseline to Recovery From Cough and Other Symptoms — 7.06; 6.76; 7.82; 9.05 Days

Primary: Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14) — -4.37; -3.56 score on a scale

Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms. — 4.1; 4.5 days — p=0.032

Primary: Number of Cough Bouts Over 4-hour Postdose Period — 139.6; 131.3; 126.4 Cough bouts — p=0.216

Primary: The Time to Resolution of Symptoms, Defined as Acute Otitis Media-Severity of Symptoms (AOM-SOS) Score of 0 or 1, According to Treatment Assignment — 20; 9; 1; 2…

Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms — 4.1; 5.0 days — p=0.0155

Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460

Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634

Primary: Detection of Respiratory Viruses — 83 participants

Primary: SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3 — 1.12; 1.14 Units on a scale — p=0.83

Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale

Primary: Warming Sensation Caused by the Excipient IFF Flavor 316 282, in a Syrup Containing Paracetamol 500 mg + Phenylephrine 10mg + Guaifenesin 200 mg Per 30 ml Syrup — 34.6 mm